These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6810328)

  • 1. [Effect of atenolol on the excretion of catecholamines and their metabolites and dihydroxyphenylalanine (DOPA) in patients with essential hypertension].
    Wocial B; Januszewicz W; Sznajderman M; Feltynowski T
    Pol Arch Med Wewn; 1982 Mar; 67(3):87-91. PubMed ID: 6810328
    [No Abstract]   [Full Text] [Related]  

  • 2. [L-DOPA test for evaluating in vivo catecholamine biosynthesis in normal persons and persons with different diseases].
    Vasil'ev VN; Matlina ESh
    Vopr Med Khim; 1977; (3):332-8. PubMed ID: 888397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [State of catecholamine and DOPA excretion in metabolic-alimentary obesity].
    Frolova IA; Beiul EA; Volkova IS; Sirota II
    Vopr Med Khim; 1974 May; 20(3):257-65. PubMed ID: 4836785
    [No Abstract]   [Full Text] [Related]  

  • 4. [Studies on the relationships between plasma-adrenaline, plasma-renin and the blood-pressure-lowering effect of the beta-receptor blockader ICI 66082 (atenolol) in patients with essential hypertension].
    Philipp T; Cordes U; Walter B; Walter U; Beyer J; Distler A
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1318-21. PubMed ID: 1029989
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hypotensive effect of ICI-66082].
    Arce Gómez E; Aguirre Roux L
    Prensa Med Mex; 1977; 42(3-4):187-93. PubMed ID: 335383
    [No Abstract]   [Full Text] [Related]  

  • 6. Changes in the excretion of catecholamines and their metabolites in patients with essential hypertension during sodium intake restriction.
    Wocial B; Januszewicz W; Chodakowska J; Feltynowski T
    Cor Vasa; 1981; 23(3):222-8. PubMed ID: 6790225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter: Atenolol and renin release.
    Sassard J; Pozet N; Vincent M; Zech PY
    N Engl J Med; 1976 Apr; 294(14):787. PubMed ID: 1256479
    [No Abstract]   [Full Text] [Related]  

  • 8. [Atenolol, pindolol and propranolol in essential hypertension: response rate and tolerance].
    Greminger P; Vetter H; Boerlin HJ; Baumgart P; Havelka J; Walger P; Lüscher T; Siegenthaler W; Vetter W
    Schweiz Med Wochenschr; 1982 Dec; 112(50):1831-5. PubMed ID: 7156966
    [No Abstract]   [Full Text] [Related]  

  • 9. [Excretion of catecholamines and their precursor DOPA in patients with meningococcal infection].
    Pokrovskiĭ VI; Sirina LK; Glotova TP; Mikhaĭlova AA
    Ter Arkh; 1976; 48(12):100-2. PubMed ID: 1013883
    [No Abstract]   [Full Text] [Related]  

  • 10. The renin-angiotensin system and the antihypertensive effect of atenolol in man.
    Mimran A; Deschodt G; Fourcade J; Barjon P
    Arch Int Pharmacodyn Ther; 1979 Sep; 241(1):100-7. PubMed ID: 526065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Short term treatment of essential arterial hypertension with atenolol: effect on the renin-angiotensin-aldosterone system and on hemodynamic parameters].
    Indovina I; Salerno L; Licata G; Pepe S; Custro N
    Clin Ter; 1983 Feb; 104(3):223-6. PubMed ID: 6861459
    [No Abstract]   [Full Text] [Related]  

  • 12. The course of aversive conditioning related to the excretion of catecholamines, DOPA and their oxidoreduction states.
    Dostálek C; Jokl J; Koch E; Krása H
    Physiologie; 1980; 17(1):45-56. PubMed ID: 6767255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Excretion of catecholamines, their precursor DOPA and vanilmandelic acid in patients with peptic ulcer].
    Kravchenko TV; Sulima TA
    Vrach Delo; 1983 Aug; (8):85-7. PubMed ID: 6415922
    [No Abstract]   [Full Text] [Related]  

  • 14. [Atenolol (Tenormin) in the treatment of hypertension].
    Kawecka-Jaszcz K; Kocemba J
    Pol Tyg Lek; 1977 Dec; 32(50):1979-81. PubMed ID: 600850
    [No Abstract]   [Full Text] [Related]  

  • 15. Haemodynamic changes during treatment of arterial hypertension with atenolol (Tenormin).
    Jensen HA; Rasmussen K; Mosbaek N
    Dan Med Bull; 1980 Jul; 27(3):153-5. PubMed ID: 7438801
    [No Abstract]   [Full Text] [Related]  

  • 16. [Changes in peripheral arterial blood flow and venous capacity in arterial hypertension and their relationship to the antihypertensive action of beta blockers].
    Caesar K; Saborowski F; Lang R; Meurer KA; Kaufmann W
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():218. PubMed ID: 613580
    [No Abstract]   [Full Text] [Related]  

  • 17. [Evaluation of the hypotensive effect of atenolol].
    Sznajderman M; Brym E; Cybulska I; Czerniewska E; Niegowska J
    Kardiol Pol; 1979; 22(6):661-6. PubMed ID: 393889
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical trial of atenolol. Study of 20 hypertensive patients].
    Martinez R; Saponaro A; Dragagna G; Forcinella M; Di Fusco W; Russo R
    Boll Soc Ital Cardiol; 1980; 25(7):705-10. PubMed ID: 7023510
    [No Abstract]   [Full Text] [Related]  

  • 19. Atenolol in hypertension a study of long-term therapy.
    Zacharias FJ; Cowen KJ; Cuthbertson PF; Johnson TB; Prestt J; Thompson J; Vickers J; Simpson WT; Tuson R
    Postgrad Med J; 1977; 53 Suppl 3():102-10. PubMed ID: 928258
    [No Abstract]   [Full Text] [Related]  

  • 20. [Atenolol, a new beta-adrenergic blocking agent, in treatment of hypertension: therapeutic effect and hemodynamic changes (author's transl)].
    Shen JQ
    Zhonghua Xin Xue Guan Bing Za Zhi; 1981 Jun; 9(2):94-8. PubMed ID: 7032869
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.